SynthesisNature communications2018
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Erratum issued Registry-linked trialOpen access · goldAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05539079 (A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance), which is not on this map. Cited by 75 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.International journal of molecular sciences · 2023Pooled it
- Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.Blood cancer journal · 2022Pooled it
- A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.Blood advances · 2020Pooled it
- Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.Human genomics · 2019Pooled it
- A prospective study of familial predisposition to plasma cell dyscrasias.Blood advances · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Article
- Profile of biological aging in first primary cancers: a pan-cancer analysis of two large-scale cohorts from the UK and Hong Kong.BMC medicine · 2025Article
- Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study.Blood cancer journal · 2025Article
- Polygenic Risk, Agent Orange Exposure, and Lymphoid Neoplasms in the Veterans Affairs Million Veteran Program.JAMA network open · 2025Article
- Therapeutic Target Discovery for Multiple Myeloma: Identifying Druggable Genes via Mendelian Randomization.Biomedicines · 2025Article
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
- FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.Seminars in hematology · 2025Review
- Germline predisposition in multiple myeloma.iScience · 2025Article
- Expression quantitative trait loci influence DNA damage-induced apoptosis in cancer.BMC genomics · 2024Article
- Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma.Leukemia · 2024Article
- Sequence variants influencing the regulation of serum IgG subclass levels.Nature communications · 2024Article
- Deciphering the genetics and mechanisms of predisposition to multiple myeloma.Nature communications · 2024Article
- Multiple myeloma.Nature reviews. Disease primers · 2024Review
- Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
70 authors at 20 institutions in 19 countries.
Molly WentDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Amit SudDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-6133-0164
Asta FörstiGerman Cancer Research Center, 69120, Heidelberg, Germany.
Britt-Marie HalvarssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden.
Niels WeinholdMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Scott KimberDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
Mark van DuinDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Gudmar ThorleifssondeCODE Genetics, Sturlugata 8, IS-101, Reykjavik, Iceland.
Amy HolroydDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
David C JohnsonDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0003-0887-3343
Ni LiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Giulia OrlandoDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Philip J LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0001-9663-4611
Mina AliHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden.
Bowang ChenGerman Cancer Research Center, 69120, Heidelberg, Germany.
Jonathan S MitchellDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Daniel F GudbjartssondeCODE Genetics, Sturlugata 8, IS-101, Reykjavik, Iceland.ORCID http://orcid.org/0000-0002-5222-9857
Rowan KuiperDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Owen W StephensMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Uta BertschGerman Cancer Research Center, 69120, Heidelberg, Germany.
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-8348-5829
Chiara CampoGerman Cancer Research Center, 69120, Heidelberg, Germany.
Obul R BandapalliGerman Cancer Research Center, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-1132-1745
Hermann EinseleUniversity Clinic of Würzburg, 97080, Würzburg, Germany.
Walter A GregoryClinical Trials Research Unit, University of Leeds, Leeds, LS2 9PH, UK.
Urban GullbergHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden.
Jens HillengassDepartment of Internal Medicine V, University of Heidelberg, 69117, Heidelberg, Germany.
Per HoffmannInstitute of Human Genetics, University of Bonn, D-53127, Bonn, Germany.
Graham H JacksonRoyal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK.
Karl-Heinz JöckelInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, D-45147, Germany.
Ellinor JohnssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden.
Sigurður Y KristinssonDepartment of Hematology, Landspitali, National University Hospital of Iceland, IS-101, Reykjavik, Iceland.
Ulf-Henrik MellqvistSection of Hematology, Sahlgrenska University Hospital, Gothenburg, 413 45, Sweden.
Hareth NahiCenter for Hematology and Regenerative Medicine, SE-171 77, Stockholm, Sweden.
Douglas EastonCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0003-2444-3247
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0001-8494-732X
Alison DunningCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
Julian PetoDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.ORCID http://orcid.org/0000-0002-4261-4583
Anthony SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Rosalind A EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.ORCID http://orcid.org/0000-0002-3698-6241
ZSofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
Kenneth MuirInstitute of Population Health, University of Manchester, Manchester, M13 9PL, UK.ORCID http://orcid.org/0000-0001-6429-988X
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.ORCID http://orcid.org/0000-0003-0843-2468
Jolanta NickelDepartment of Internal Medicine V, University of Heidelberg, 69117, Heidelberg, Germany.
Markus M NöthenInstitute of Human Genetics, University of Bonn, D-53127, Bonn, Germany.
Thorunn RafnardeCODE Genetics, Sturlugata 8, IS-101, Reykjavik, Iceland.
Fiona M RossWessex Regional Genetics Laboratory, University of Southampton, Salisbury, SP2 8BJ, UK.
Miguel Inacio da Silva FilhoGerman Cancer Research Center, 69120, Heidelberg, Germany.
Hauke ThomsenGerman Cancer Research Center, 69120, Heidelberg, Germany.
Ingemar TuressonHematology Clinic, Skåne University Hospital, SE-221 85, Lund, Sweden.
Annette VangstedDepartment of Haematology, University Hospital of Copenhagen at Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.
Niels Frost AndersenDepartment of Haematology, Aarhus University Hospital, Tage-Hansens Gade 2, DK-8000, Aarhus C, Denmark.
Anders WaageDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Box 8905, N-7491, Trondheim, Norway.
Brian A WalkerMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Anna-Karin WihlborgHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden.
Annemiek BroylDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Faith E DaviesMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Unnur ThorsteinsdottirdeCODE Genetics, Sturlugata 8, IS-101, Reykjavik, Iceland.
Christian LangerDepartment of Internal Medicine III, University of Ulm, D-89081, Ulm, Germany.
Markus HanssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden.ORCID http://orcid.org/0000-0002-7715-4548
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, 69117, Heidelberg, Germany.
Martin KaiserDivision of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Kari StefanssondeCODE Genetics, Sturlugata 8, IS-101, Reykjavik, Iceland.
Gareth J MorganMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Kari HemminkiGerman Cancer Research Center, 69120, Heidelberg, Germany. K.Hemminki@dkfz-heidelberg.de.
Björn NilssonHematology and Transfusion Medicine, Department of Laboratory Medicine, BMC B13, Lund University, SE-221 84, Lund, Sweden. bjorn.nilsson@med.lu.se.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK. richard.houlston@icr.ac.uk.ORCID http://orcid.org/0000-0002-5268-0242
PRACTICAL consortium
Institute of Cancer Research · GBGerman Cancer Research Center · DEUniversity of Cambridge · GBLund University · SEdeCODE Genetics (Iceland) · ISNational Cancer Institute · USErasmus MC Cancer Institute · NLHeidelberg University · DEUniversity of Arkansas for Medical Sciences · USKarolinska Institutet · SEUniversity of Southern California · USAmerican Cancer Society · USBrigham and Women's Hospital · USManchester Academic Health Science Centre · GBTranslational Research Institute · AUUniversity of Bonn · DEUniversity of Surrey · GBUniversity of Washington · USAarhus University · DKAarhus University Hospital · DK
Funding
Tumor Cell-Microenvironment Interactions in the Molecular Pathogenesis of MultiplP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI YACCOBY, SHMUEL · 1993 to 2013
$49.7MUnderstanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI CHARLES A O'BRIEN · 2018 to 2026
$23.0MEpidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MImputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9MCancer Research UK 14136Cancer Research UK 16491Cancer Research UK 16565Cancer Research UK 17528Medical Research Council G1000143Medical Research Council MR/M012190/1NCI NIH HHS P01 CA055819NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INIGMS NIH HHS P20 GM125503Wellcome Trust
Abstract
Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight into the biological basis of MM.
Indexed as
Genetic Predisposition to DiseasePolymorphism, Single NucleotideBayes TheoremChromatinChromatin ImmunoprecipitationFemaleGene Expression RegulationGenome-Wide Association StudyGenotypeHumansMaleMultiple MyelomaPromoter Regions, GeneticQuality ControlQuantitative Trait LociRiskChromatin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05539079ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.